
Elanco to launch product that reduces dairy cattle methane emissions
Elanco has called Bovaer a potential blockbuster, meaning it could ring up annual sales of at least $100 million.
Elanco has called Bovaer a potential blockbuster, meaning it could ring up annual sales of at least $100 million.
The company said the site footprint will not expand, but the company will fill in the property with more buildings and equipment. Manufacturing capacity will almost triple there.
Lilly said the new investment will allow it to hire 200 more workers at the complex, including engineers, scientists, and lab technicians, for a total of 900 full-time workers when it is fully operational.
Novartis Manufacturing LLC told a committee of the City-County Council on Monday evening that it plans to spend up to $125 million to construct and equip a 79,000-square-foot-building for radiopharmaceutical manufacturing and distribution on the city’s west side.
The Indiana Board of Nursing has accredited the university to accept 48 students a year, meaning the program will have nearly 200 students when it is fully enrolled across four years.
The roster of radiopharmaceuticals players in the Indianapolis area has surged in the past few years to include some of the world’s leading pharmaceutical companies, attracted by the potential for significant growth.
In a series of lawsuits Lilly filed in September and October in federal court, the drugmaker had accused Totality Medispa of trademark infringement, false advertising, unfair competition and unfair trade practices.
The U.S. Food and Drug Administration is convening a panel of independent experts on June 10 to discuss donanemab’s safety and effectiveness, including the results in patients in a clinical trial.
In response, Indiana Hospital Association President Brian Tabor said the Rand report “continues to paint a distorted view of health care in our state.”
For the first time, federal regulations will cover the nearly 50 dumps spread across 14 locations in Indiana that were previously exempted from cleanup provisions.
A report issued Monday by BioCrossroads says Indiana life sciences companies saw a decrease in capital and investments last year, but made a significantly higher contribution to the state’s economy than they did the previous year.
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
The Carmel medical group is gaining a reputation as a training and education center. It holds courses for high school and college students in anatomy as well as surgeons going out on their own after residencies and fellowships.
More than four years after the start of the COVID-19 pandemic, many Indiana hospitals are still barely breaking even and their financial viability remains at risk, according to a report released Thursday morning by the Indiana Hospital Association.
Doctors and pharmacies have reported huge demand for Mounjaro and Zepbound in recent months, causing widespread shortages of the popular drugs.
Several victims have filed lawsuits against Otolaryngology Associates, saying the practice waited about six weeks to inform victims of the data breach.
Tabor, 49, who has acted as chief advocate the state’s 170 hospitals since 2016, said he is looking forward to spending more time with his family and pursuing his longtime hobby, birdwatching.
The company plans to develop at least 12 buildings totaling more than 1.6 million square feet. The project is expected to anchor the LEAP Research and Innovation District northwest of Lebanon.
Indianapolis-based NICO recently wrapped up a large clinical trial that tested the company’s minimally invasive tools and technology for brain surgery in patients with hemorrhagic stroke. Now it faces a major decision.
In the past five years, the nation’s largest Catholic health system has unloaded more than a dozen hospitals across the country, from New York to Alabama, as it restructures amid a growing tide of red ink.